MPXV A29L Monoclonal Antibody & Recombinant Antigens for Mpox Rapid Test & ELISA IVD Development
Monkeypox virus (MPXV) is a double-stranded DNA virus belonging to the genus Orthopoxvirus within the family Poxviridae, with a genome of approximately 197 kilobases encoding around 190 open reading frames. MPXV is classified into two major clades: Clade I (formerly the Central African or Congo Basin clade), which is associated with more severe disease and higher transmission, and Clade II (formerly the West African clade), which includes the Clade IIa and Clade IIb subclades — the latter responsible for the 2022 global multi-country outbreak. The A29L protein (also annotated as A29R in some genome references) is one of the major envelope proteins of MPXV, functioning as the mature virion surface membrane protein (MVP). A29L is highly conserved across the orthopoxvirus family — including variola (smallpox), vaccinia (VACV), and cowpox viruses — with >90% amino acid sequence identity, making it an ideal target for both broad orthopoxvirus detection and MPXV-specific immunological applications. As an immunodominant antigen accessible on the viral surface, A29L is the leading target epitope for LFA rapid antigen test strip development and the most widely used recombinant antigen for MPXV serology ELISA assays.
The emergence of MPXV as a global public health threat was dramatically illustrated by the 2022 Clade IIb outbreak: beginning in May 2022, the virus spread rapidly across more than 100 countries outside its traditional endemic range in Africa, with over 86,000 confirmed cases reported to WHO by the end of 2023. This was followed in 2024 by an escalating Clade I outbreak in the Democratic Republic of Congo and neighbouring African countries, which WHO declared a Public Health Emergency of International Concern (PHEIC) in August 2024 — only the second time Mpox had triggered such a declaration. The 2024 Clade I outbreak is of particular concern due to higher case fatality rates and evidence of sustained community transmission. The dual burden of Clade I in Africa and residual Clade IIb transmission globally has created urgent and sustained demand for Mpox diagnostic tools at both point-of-care and laboratory levels, with WHO conducting emergency rapid diagnostic test (RDT) evaluations to accelerate deployment of quality-assured Mpox tests.
For IVD developers, the MPXV diagnostic landscape requires two distinct assay types that Sekbio's panel directly supports. First, LFA rapid antigen detection using the anti-A29L monoclonal antibody MVA29L02C: this directly detects MPXV A29L protein in skin lesion swab or vesicular fluid samples, providing a result within 15–20 minutes at point-of-care — the preferred format for outbreak response and decentralised testing. Second, ELISA or CLIA serology using recombinant MPXV antigens (MVPA29L and MVPB6R) as plate-coating antigens to detect anti-MPXV IgG and IgM antibodies in serum — used for seroprevalence surveys, vaccine immunogenicity studies, and post-exposure surveillance. Sekbio provides all three products from a single ISO 13485-certified source, simplifying the raw material supply chain for Mpox IVD development programmes.
Three complementary MPXV raw materials — anti-A29L antibody plus recombinant A29L and B6R antigens — for complete Mpox LFA, ELISA, and CLIA IVD development.
| Catalog No. | Product Name | Type | Purity | Intended Use | Storage |
|---|---|---|---|---|---|
| MVA29L02C | Anti-MPXV A29L Monoclonal Antibody (HEK293) | mAb (Mouse IgG1) | >95% SDS-PAGE | LFA / ELISA / CLIA Antigen Detection | −20°C / +2–8°C <1 month |
| MVPA29L | Recombinant MPXV A29L Antigen (14 kDa, His-tag) | Recombinant Protein (E.coli) | >90% SDS-PAGE | ELISA / CLIA Serology Coating Antigen | Per CoA |
| MVPB6R | Recombinant MPXV B6R Protein (45.7 kDa, N-TrxA; C-6His) | Recombinant Protein (E.coli) | >90% SDS-PAGE | ELISA / CLIA / CMIA / POCT Serology | −80°C / +2–8°C <1 month |
MVPA29L: 116 aa, E.coli expressed, His-tag. MVPB6R: N-TrxA & C-6His tag, E.coli expressed, PBS pH 7.4. MOQ 1 mg for all products. OEM quantities available. Contact info@sekbio.com for datasheets and bulk pricing.
A complete, validated MPXV raw material panel from a single ISO 13485-certified source, engineered for rapid test and serology IVD development.
MVA29L02C is produced using HEK293 mammalian cell expression rather than conventional hybridoma ascites methods, providing authentic mammalian glycosylation, superior folding fidelity, and enhanced lot-to-lot consistency. Protein A affinity purification delivers >95% purity by SDS-PAGE. HEK293-expressed antibodies typically demonstrate superior binding kinetics and stability in sandwich immunoassay formats compared to ascites-derived alternatives — important for maximising LFA rapid test sensitivity.
Sekbio provides recombinant antigens for two distinct MPXV protein targets: A29L (major envelope protein, 14 kDa, 116 aa, the primary antigen detection and serology target) and B6R (DNA polymerase processivity factor, 45.7 kDa, a key serological antigen for orthopoxvirus immune response studies). The dual-antigen approach enables developers to build multi-antigen ELISA panels for higher sensitivity serology or to evaluate alternative antigen targets for different assay platforms.
MVA29L02C antibody is validated for LFA (lateral flow rapid antigen test), ELISA, and CLIA platforms. Recombinant A29L and B6R antigens are validated for ELISA, CLIA, CMIA, and POCT formats. This multi-platform compatibility allows IVD developers to use a single set of Sekbio MPXV raw materials across rapid test and laboratory-based diagnostic product lines — from field-deployable point-of-care strips to high-throughput hospital serology platforms.
MVA29L02C antibody: >95% purity by SDS-PAGE (Protein A purified). MVPA29L and MVPB6R recombinant antigens: >90% purity by SDS-PAGE. High-purity antigens minimise background in ELISA serology assays and reduce non-specific binding in LFA formats. Consistent purity across lots ensures reproducible assay performance during kit manufacturing scale-up. ISO 13485 QMS with inter-batch CV <10%.
Sekbio's MPXV products were developed and characterised in the context of the 2022 Clade IIb global outbreak, providing real-world assay development validation data. The A29L target has been confirmed as the most robust epitope for both antigen detection and serology across Clade I and Clade II MPXV strains. Our MPXV panel supports the current dual-clade global situation — both Clade I (2024 Africa PHEIC) and Clade IIb (ongoing global transmission).
Sekbio supplies MPXV antibody and antigen products to OEM IVD kit manufacturers worldwide, supporting CE IVD, WHO EUL, and national regulatory submissions. ISO 13485-certified manufacturing with full batch documentation and traceability. MOQ 1 mg for R&D; gram-scale for commercial production. Sekbio has established supply channels supporting Mpox diagnostic manufacturers responding to both the 2022 and 2024 outbreaks across Africa, Europe, and Asia.
MPXV antibody and antigen panel for rapid antigen test development, serology, outbreak surveillance, and CLIA confirmatory assay construction.
Anti-A29L antibody MVA29L02C is the primary raw material for LFA rapid Mpox antigen detection strip development. The target sample type is skin lesion swab or vesicular fluid — the matrices with highest MPXV viral load during symptomatic infection. LFA format enables results within 15–20 minutes without laboratory equipment, making it the preferred diagnostic tool for emergency departments, sexual health clinics, and outbreak response teams. WHO has evaluated and listed several A29L-targeting MPXV RDTs under its Emergency Use Listing process. Contact info@sekbio.com for LFA development support and sample supply.
Recombinant MPXV A29L (MVPA29L) and B6R (MVPB6R) antigens are ideal for ELISA and CLIA serology plate coating to detect anti-MPXV IgG and IgM antibodies in serum. Seroepidemiological studies using these antigens measure population-level MPXV immunity, vaccine immunogenicity in clinical trials (MVA-BN/JYNNEOS), and cross-reactive orthopoxvirus immunity from historical smallpox vaccination. Multi-antigen ELISA panels using both A29L and B6R improve sensitivity and specificity for anti-orthopoxvirus serology compared to single-antigen formats.
The 2022 Clade IIb outbreak and 2024 Clade I Africa PHEIC demonstrated that rapid scale-up of Mpox diagnostic capacity requires pre-positioned raw material supply. Sekbio can supply MPXV antibody and antigen products in advance for institutional preparedness stockpiling by national laboratories, WHO, UNICEF, and global health procurement organisations. ISO 13485 manufacturing with documented shelf-life stability data supports strategic reserve procurement. Visit our Products page for the full infectious disease IVD raw material portfolio, or contact us to discuss strategic supply.
For clinical laboratories requiring higher sensitivity than LFA provides, CLIA (chemiluminescence immunoassay) using MVA29L02C antibody for antigen detection or MVPB6R/MVPA29L for serology delivers quantitative results with significantly lower limits of detection. CLIA Mpox antigen detection is particularly valuable for samples from immunocompromised patients where viral antigen concentration may be lower, or for monitoring antigen clearance during antiviral treatment with tecovirimat (TPOXX). Quantitative CLIA data also supports clinical research characterising Mpox disease severity and treatment response biomarkers.
Technical and commercial questions from IVD R&D engineers and procurement teams.
A29L (also annotated A29R) is the major envelope protein (MVP) of monkeypox virus, located on the surface of mature virions. It is immunodominant — meaning it generates strong immune responses during natural infection and vaccination — and highly conserved across all MPXV clades and related orthopoxviruses (>90% amino acid identity with vaccinia A27L). These properties make A29L the optimal target for both antigen detection (using anti-A29L antibody MVA29L02C in LFA or CLIA) and serology (using recombinant A29L protein MVPA29L as plate coating antigen in ELISA). Its surface accessibility enables efficient capture and detection in sandwich immunoassay formats without sample denaturation.
Sekbio's MPXV panel includes: MVA29L02C (anti-MPXV A29L mAb, Mouse IgG1, HEK293 expressed, Protein A purified, >95% SDS-PAGE, PBS pH 7.4, for LFA/ELISA/CLIA antigen detection), MVPA29L (recombinant MPXV A29L, 14 kDa, 116 aa, His-tag, E.coli, >90% SDS-PAGE, serology coating antigen), and MVPB6R (recombinant MPXV B6R, 45.7 kDa, N-TrxA & C-6His, E.coli, >90% SDS-PAGE, PBS pH 7.4, for ELISA/CLIA/CMIA/POCT). All products available from MOQ 1 mg with CoA.
MVA29L02C is an anti-A29L antibody used to detect MPXV A29L antigen directly in patient samples — this is an antigen detection assay, used during active infection. MVPA29L and MVPB6R are recombinant viral proteins used as coating antigens in ELISA or CLIA to detect anti-MPXV antibodies (IgG/IgM) in patient serum — this is a serology assay, used to diagnose past infection or assess immune response. Antigen detection is preferred for acute case diagnosis; serology is used for seroprevalence surveys and immunity assessment. Developers can use both types simultaneously for a comprehensive Mpox diagnostic panel.
HEK293 mammalian cell expression provides authentic human-type glycosylation patterns and correct protein folding, resulting in higher biological activity, enhanced stability under assay conditions, and superior lot-to-lot consistency compared to mouse ascites-derived antibodies. Protein A affinity purification from HEK293 culture supernatant yields >95% purity by SDS-PAGE with minimal host cell protein contamination. For sandwich immunoassay applications in LFA and CLIA, these properties translate to better coating efficiency, lower background, and more consistent assay performance across production lots.
MOQ is 1 mg for all three products. MVA29L02C antibody: store at −20°C long-term; +2°C to +8°C for up to 1 month; PBS pH 7.4. MVPA29L antigen: storage conditions per CoA; E.coli expressed, His-tagged, PBS buffer. MVPB6R antigen: store at −80°C long-term; +2°C to +8°C for up to 1 month; PBS pH 7.4. Avoid repeated freeze/thaw cycles for all products. OEM quantities (10 mg–gram scale) available with consistent lot-to-lot performance.
Yes. Sekbio is an ISO 13485-certified manufacturer that has supported multiple OEM Mpox IVD development programmes through the 2022 Clade IIb global outbreak and the 2024 Clade I Africa PHEIC. We provide full batch documentation, Certificate of Analysis, and technical support packages for CE IVD (EU IVDR), WHO Emergency Use Listing, and national regulatory submissions. Contact info@sekbio.com to request datasheets, sample vials, or OEM pricing for any MPXV product. Visit our Platforms page for antibody development and custom antigen expression services.
Request the full technical datasheet, product specifications, or discuss OEM supply for your Mpox IVD development programme.